What is Centivax?
Centivax is at the forefront of a new era in biotechnology, aiming to accelerate humanity's transition to a post-pathogen world. Founded at the confluence of advancements in biotechnology, big data, and immunology, the company has developed a groundbreaking broad-spectrum (universal) vaccine technology. This technology has already yielded a universal influenza vaccine capable of protecting against all forms of human flu. Centivax is now applying this platform to critical diseases such as HIV and coronaviruses, with plans to expand to dengue, malaria, tuberculosis, herpes, RSV, and the common cold. The company's mission is to provide lasting protection against infectious diseases, building on centuries of scientific progress with modern technological capabilities.
How much funding has Centivax raised?
Centivax has raised a total of $92M across 3 funding rounds:
Angel/Seed
$10M
Series A
$45M
Unspecified
$37M
Angel/Seed (2022): $10M with participation from Global Health Investment Corporation and The NFX
Series A (2025): $45M led by Kendall Capital Partners, Base4, The NFX, BOLD Capital Partners, Future Technologies, and Amplify Partners
Unspecified (2026): $37M supported by Meiji Holdings and Kendall Capital Partners
Key Investors in Centivax
Kendall Capital Partners
Kendall Capital Partners is an investment firm focused on breakthroughs that redefine health at scale. The company supports innovative biotech startups and collaborates with established pharmaceutical companies to drive advancements in healthcare. Their portfolio includes companies working on affordable monoclonal antibodies, novel vaccine delivery systems, and AI-driven medical devices. Kendall Capital Partners aims to enhance healthcare accessibility and improve patient outcomes through strategic investments and partnerships.
The NFX
NFX is a venture capital firm that focuses on investing in pre-seed and seed stage startups, aiming to support exceptional founders who are building transformative companies across various sectors. Their investment areas include gaming, generative AI, proptech, space, fintech, marketplaces, and crypto, with a strong presence in Silicon Valley, Israel, Europe, and Latin America. In addition to funding, NFX also provides software tools and educational resources for founders, including a fundraising network and masterclass on network effects. They foster a community of over 400 founders through the NFX Guild, empowering startups to succeed from seed stage to profitability.
Meiji Holdings
Meiji Holdings is a Japanese conglomerate founded in 2009 through the merger of Meiji Seika and Meiji Dairies. The company operates as a major global confectionery manufacturer while also maintaining significant business divisions in pharmaceuticals, healthcare products, and dairy goods. As one of the world's leading confectionery companies, Meiji Holdings produces a diverse range of food products and healthcare solutions primarily serving markets across Asia and the Pacific region.
What's next for Centivax?
With substantial enterprise-level backing and a recent strategic investment, Centivax is poised to scale its operations and expedite the development and deployment of its universal vaccine technologies. The significant capital infusion, totaling $92M, will likely fuel further research and development, clinical trials, and manufacturing capabilities. This strategic financing suggests a move towards broader market penetration and the potential to address a wide array of global health challenges, solidifying Centivax's role in shaping the future of infectious disease control.
See full Centivax company page
